{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:08:41Z","timestamp":1778476121729,"version":"3.51.4"},"reference-count":11,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jid.2025.05.032","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:38:13Z","timestamp":1751917093000},"page":"3201-3202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Justification to Using the FDA Adverse Event Reporting System for Hypothesis Generation Regarding Benzoyl Peroxide"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0107-148X","authenticated-orcid":false,"given":"Kerry","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-3557","authenticated-orcid":false,"given":"Fatemeh","family":"Jafarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.05.032_bib1","article-title":"Occupational benzene exposure and skin cancers: a systematic review and meta-analysis","volume":"2","author":"Angelini","year":"2025","journal-title":"Occup Med (Lond)"},{"key":"10.1016\/j.jid.2025.05.032_bib2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/jamadermatol.2024.6443","article-title":"The role of formulation in benzene formation in benzoyl peroxide products","volume":"161","author":"Barbieri","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.05.032_bib3","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaad.2024.07.1504","article-title":"No association of benzoyl peroxide use with acute myeloid leukemia and hematologic malignancies in a multi-center retrospective study","volume":"91","author":"Chan","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.05.032_bib7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jaad.2024.07.011","article-title":"Benzoyl peroxide for acne treatment is not associated with an increased risk of malignancy: a retrospective cohort study","volume":"91","author":"Garate","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.05.032_bib8","doi-asserted-by":"crossref","DOI":"10.1289\/EHP13984","article-title":"Benzoyl peroxide drug products form benzene","volume":"132","author":"Kucera","year":"2024","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jid.2025.05.032_bib9","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jid.2024.09.009","article-title":"Evaluation of benzene presence and formation in benzoyl peroxide drug products","volume":"145","author":"Kucera","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.05.032_bib10","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1289\/ehp.1002546","article-title":"Global gene expression profiling of a population exposed to a range of benzene levels","volume":"119","author":"McHale","year":"2011","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jid.2025.05.032_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cbi.2009.12.014","article-title":"Implications of latency period between benzene exposure and development of leukemia--a synopsis of literature","volume":"184","author":"Triebig","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.jid.2025.05.032_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2025.05.025","article-title":"Response to Yang et al.\u2019s \u201cA disproportionality Analysis on benzoyl peroxide and Its Risk of Malignancy Using the FDA Adverse Event Reporting System\u201d","author":"Veenstra","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.05.032_bib13","article-title":"A disproportionality analysis on benzoyl peroxide and its risk of malignancy using the FDA Adverse Event Reporting System [e-pub ahead of print]","author":"Yang","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2025.05.032_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/jocd.16787","article-title":"A comprehensive study on adverse reactions of benzoyl peroxide (BPO) in dermatological aesthetics utilizing the FAERS database","volume":"24","author":"Zhou","year":"2025","journal-title":"J Cosmet Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25005597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25005597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:23:29Z","timestamp":1778473409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25005597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022202X25005597"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.05.032","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Justification to Using the FDA Adverse Event Reporting System for Hypothesis Generation Regarding Benzoyl Peroxide","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.05.025","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}